Cargando…

Angiopoietin-like protein 4 and cardiovascular function in COPD

INTRODUCTION: The coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) is frequent and might be inter-related through inflammation-related processes reflected by specific markers. Here, we studied angiopoietin-like protein 4 (ANGPTL4), an upcoming cardiovascul...

Descripción completa

Detalles Bibliográficos
Autores principales: Waschki, B, Kirsten, AM, Holz, O, Meyer, T, Lichtinghagen, R, Rabe, KF, Magnussen, H, Welte, T, Watz, H, Janciauskiene, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133419/
https://www.ncbi.nlm.nih.gov/pubmed/27933182
http://dx.doi.org/10.1136/bmjresp-2016-000161
_version_ 1782471258370211840
author Waschki, B
Kirsten, AM
Holz, O
Meyer, T
Lichtinghagen, R
Rabe, KF
Magnussen, H
Welte, T
Watz, H
Janciauskiene, S
author_facet Waschki, B
Kirsten, AM
Holz, O
Meyer, T
Lichtinghagen, R
Rabe, KF
Magnussen, H
Welte, T
Watz, H
Janciauskiene, S
author_sort Waschki, B
collection PubMed
description INTRODUCTION: The coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) is frequent and might be inter-related through inflammation-related processes reflected by specific markers. Here, we studied angiopoietin-like protein 4 (ANGPTL4), an upcoming cardiovascular marker, in stable COPD, and its relationship to cardiovascular function with respect to well-known CVD risk factors. METHODS: In a prospective COPD cohort study, we investigated serum ANGPTL4 levels, vascular status (ankle–brachial index (ABI)) and cardiac function (N-terminal pro-B-type natriuretic peptide (NT-proBNP)) as well as airflow limitation, objectively measured physical activity, the metabolic syndrome, high-sensitive C reactive protein (hs-CRP) and other CVD risk factors at 2 time points. We initially studied 74 stable COPD patients and 18 controls. For internal validation, we additionally studied 160 COPD patients of a former visit. RESULTS: ANGPTL4 was significantly elevated in COPD patients compared with controls (p=0.026). After correction for traditional CVD risk factors, including hs-CRP, higher levels of ANGPTL4 were independently associated with lower ABI (p=0.023) and higher NT-proBNP (p<0.001). These findings were confirmed in the internal validation analysis, which included echocardiographic assessments. CONCLUSIONS: Serum ANGPTL4 is independently associated with cardiovascular function in COPD and might qualify as a biomarker reflecting a pathogenic link between COPD and CVD.
format Online
Article
Text
id pubmed-5133419
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51334192016-12-08 Angiopoietin-like protein 4 and cardiovascular function in COPD Waschki, B Kirsten, AM Holz, O Meyer, T Lichtinghagen, R Rabe, KF Magnussen, H Welte, T Watz, H Janciauskiene, S BMJ Open Respir Res Chronic Obstructive Pulmonary Disease INTRODUCTION: The coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) is frequent and might be inter-related through inflammation-related processes reflected by specific markers. Here, we studied angiopoietin-like protein 4 (ANGPTL4), an upcoming cardiovascular marker, in stable COPD, and its relationship to cardiovascular function with respect to well-known CVD risk factors. METHODS: In a prospective COPD cohort study, we investigated serum ANGPTL4 levels, vascular status (ankle–brachial index (ABI)) and cardiac function (N-terminal pro-B-type natriuretic peptide (NT-proBNP)) as well as airflow limitation, objectively measured physical activity, the metabolic syndrome, high-sensitive C reactive protein (hs-CRP) and other CVD risk factors at 2 time points. We initially studied 74 stable COPD patients and 18 controls. For internal validation, we additionally studied 160 COPD patients of a former visit. RESULTS: ANGPTL4 was significantly elevated in COPD patients compared with controls (p=0.026). After correction for traditional CVD risk factors, including hs-CRP, higher levels of ANGPTL4 were independently associated with lower ABI (p=0.023) and higher NT-proBNP (p<0.001). These findings were confirmed in the internal validation analysis, which included echocardiographic assessments. CONCLUSIONS: Serum ANGPTL4 is independently associated with cardiovascular function in COPD and might qualify as a biomarker reflecting a pathogenic link between COPD and CVD. BMJ Publishing Group 2016-10-31 /pmc/articles/PMC5133419/ /pubmed/27933182 http://dx.doi.org/10.1136/bmjresp-2016-000161 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Chronic Obstructive Pulmonary Disease
Waschki, B
Kirsten, AM
Holz, O
Meyer, T
Lichtinghagen, R
Rabe, KF
Magnussen, H
Welte, T
Watz, H
Janciauskiene, S
Angiopoietin-like protein 4 and cardiovascular function in COPD
title Angiopoietin-like protein 4 and cardiovascular function in COPD
title_full Angiopoietin-like protein 4 and cardiovascular function in COPD
title_fullStr Angiopoietin-like protein 4 and cardiovascular function in COPD
title_full_unstemmed Angiopoietin-like protein 4 and cardiovascular function in COPD
title_short Angiopoietin-like protein 4 and cardiovascular function in COPD
title_sort angiopoietin-like protein 4 and cardiovascular function in copd
topic Chronic Obstructive Pulmonary Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133419/
https://www.ncbi.nlm.nih.gov/pubmed/27933182
http://dx.doi.org/10.1136/bmjresp-2016-000161
work_keys_str_mv AT waschkib angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT kirstenam angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT holzo angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT meyert angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT lichtinghagenr angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT rabekf angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT magnussenh angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT weltet angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT watzh angiopoietinlikeprotein4andcardiovascularfunctionincopd
AT janciauskienes angiopoietinlikeprotein4andcardiovascularfunctionincopd